Introduction Excess release of catecholamines and prostaglandins has been shown to mediate pro-metastatic processes of stress and surgery, specifically during the critical perioperative period. Material and methods Here, in two randomised placebo controlled clinical trials in colorectal (CRC, n=34) and in breast cancer patients (BC, n=38), we tested the combined 20 day perioperative use of the b-blocker, propranolol, and the COX2-inhibitor, etodolac, initiated 5 days before surgery. Tumour samples were collected during surgery, and were subjected to histological analyses, whole genome mRNA profiling, and transcriptional control pathways analyses. In BC patients, four blood samples were also collected perioperatively. Results and discussions Drugs were well tolerated, with adverse effects equivalent to placebo. In blood samples, treatment reduced serum IL-6 and CRP levels even before surgery, improved markers of NK cytotoxicity, and enhanced induced production of IFNg and IL-12, without affecting anti-inflammatory soluble factors (cortisol and IL-10). In both studies, whole genome mRNA profiling of excised tumours showed decreased epithelial-to-mesenchymal transition (EMT); downregulation of the transcriptional activity of CREB, NFkB, GATA family, and STAT3; reduced presence of tumor-associated monocytes; and increased presence of NK cells in CRC and B cells in BC tissue. The tumour proliferation marker Ki67 was tested in BC patients, and was significantly reduced by drug treatment. In CRC patients, three-year follow-up showed large but statistically insignificant improvement in disease free survival (DFS) in the treatment group (1/15 vs 5/ 19), further suggesting the safety of the paradigm. Conclusion These findings suggest a critical impact to the short pre-operative period, clearly indicate the efficacy of this combined drug regimen, and suggest its metastatic-reducing impact, which should be tested in larger clinical trials. Such a stress-inflammatory-reducing approach can be exploited during the critical perioperative period, potentially improving longterm survival rates. Introduction Active areas of research in head and neck squamous cell carcinoma (HNSCC) include the identification of novel targets, exploration of resistance mechanisms to current therapies, and identification of combination strategies. Recent progress in molecular biology and translational research has initiated an era of personalised medicine in head and neck clinical oncology. The genetic information defined by biomarker analysis in tumours and individuals is indispensable for the administration of molecular targeting agents. PO-025Carcinogenesis is determined by various epigenetic events, such as histone deacetylation. Inhibition of histone deacetylase enzymes (HDACs) has been well documented as an attractive target for the development of chemotherapeutic drugs. The purpose of this study was to investigate the effects of Entinostat, an HDAC inhibitor, on cell viability and cell cycle in oral squamous cell carcinoma (OSCC) cell lines. Th...
The increment in the demand for high-frequency monolithic integrated circuits has driven the development of waveguide-to-microstrip transition that allow their characterization and integration with waveguide components. Unfortunately, some of these transitions currently feature a rather narrow bandwidth, especially when the substrate is inserted transversal to the propagation direction of the waveguide. Here we present a new design that overcomes this problem. The transisition was originally designed for a bandwidth of 33.5–60 GHz (extended V-Band) with the simulation results showing reflections below −19.5 dB in a fractional bandwidth of 55% and, moreover, can be scaled to other frequencies keeping good electrical characteristics. To validate the design we show the scaling, construction, and measurement in an extended Q-band (27–50 GHz) with the additional advantage of having a standard impedance of 50 Ω. The most novel feature is a staggered air cavity for the microstrip and planar probe, which generates return losses better than 20 dB in a fractional bandwidth of 53%.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.